FDA Approves Novartis’ New IL-17A-Blocking Psoriasis Drug Cosentyx
Novartis' Cosentyx is the first approved human monoclonal antibody that selectively binds to interleukin IL-17A.
Tag: Novartis
All
LatestSorry, No Posts Found
All
Latest
Letybo, a Botulinum Toxin Recently Approved in US, Expands to Malaysia
The botulinum toxin product from Hugel expands its global reach with training and launch events.
